Literature DB >> 1378953

Specificity and potency of N-methyl-D-aspartate glycine site antagonists and of mephenesin on the rat spinal cord in vitro.

E Pralong1, J D Millar, D Lodge.   

Abstract

The potency, specificity and reversibility of various presumed glycine site N-methyl-D-aspartate (NMDA) antagonists was studied on neonatal rat spinal cord using the grease gap technique. 5,7-Dichlorokynurenate was the most potent and specific glycine site antagonist among the compounds tested. On the other hand mephenesin was a weak non-specific excitatory amino acid (EAA) antagonist; reduction of the response to NMDA was not reversed by D-serine. The EAA antagonist properties of mephenesin could explain its mode of action at the cellular level. The lack of effect of D-serine alone suggests that in our experimental conditions glycine sites on spinal neurones are occupied by an endogenous ligand.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378953     DOI: 10.1016/0304-3940(92)90646-o

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  4 in total

1.  Possible NMDA antagonist properties of drugs that affect high pressure neurological syndrome.

Authors:  M A Shuker; F Bowser-Riley; S N Davies
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

2.  Effects of D-cycloserine and (+)-HA-966 on the locomotor stimulation induced by NMDA antagonists and clonidine in monoamine-depleted mice.

Authors:  M L Carlsson; G Engberg; A Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1994

3.  Anticonvulsant Effect of Guaifenesin against Pentylenetetrazol-Induced Seizure in Mice.

Authors:  Mojtaba Keshavarz; Alireza Showraki; Masoumeh Emamghoreishi
Journal:  Iran J Med Sci       Date:  2013-06

4.  Efficacy and safety of guaifenesin for upper back, neck, and shoulder pain: a Phase II proof-of-concept, multicenter, placebo-controlled, repeat-dose, parallel-group study.

Authors:  Agron Collaku; Yong Yue; Kenneth Reed
Journal:  J Pain Res       Date:  2017-03-21       Impact factor: 3.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.